SIBO Hydrogen Breath Testing: Lactulose, Glucose & Methane Protocols Explained

What Is SIBO — and Why the Definition Still Matters

SIBO stands for Small Intestinal Bacterial Overgrowth, and its classical definition hinges on a number: bacteria exceeding >10⁵ CFU/mL in the proximal small intestine as measured by jejunal aspirate culture. That threshold reflects the fact that the small bowel is normally a relatively sparse microbial environment — counts under <10³ CFU/mL are considered healthy. Some researchers now accept >10³ CFU/mL as clinically significant, particularly when combined with symptoms.

The jejunal aspirate, while still the diagnostic gold standard in academic settings, is invasive, expensive, prone to contamination, and rarely practical in community gastroenterology. This gap is precisely why breath testing became the workhorse diagnostic: it's non-invasive, relatively low-cost, and correlates reasonably well with symptoms — even if its accuracy is legitimately contested.

Understanding SIBO also requires clearing up a terminology issue. What was once called "methane SIBO" is now formally designated intestinal methanogen overgrowth (IMO), because the culprit — Methanobrevibacter smithii — is an archaeon, not a bacterium. The distinction matters both scientifically and clinically: methanogens require a different treatment approach, and conflating them with bacteria leads to suboptimal protocols.

Three Distinct Overgrowth Patterns, Three Different Clinical Pictures

Hydrogen-Dominant SIBO

This is the most common and most studied form. Organisms like Prevotella and Klebsiella ferment carbohydrates in the small intestine, producing hydrogen gas. Clinically, patients present with bloating, abdominal pain, and diarrhea-predominant symptoms. Hydrogen is the primary substrate measured in standard breath tests, and rifaximin monotherapy has the best evidence base here.

Intestinal Methanogen Overgrowth (IMO)

Methanobrevibacter smithii consumes hydrogen produced by other organisms and converts it to methane (CH₄). Methane gas slows intestinal transit, which is why IMO presents as constipation-predominant — often stubborn, hard-to-treat constipation that doesn't respond to fiber or osmotic laxatives. A breath test reading of ≥10ppm CH₄ at any point during the test is diagnostic for IMO. Because M. smithii is an archaeon with a different cell wall structure than bacteria, it's resistant to many standard antibiotics — hence the combination protocol with neomycin.

Hydrogen Sulfide SIBO

The least understood and most underdiagnosed variant. Sulfate-reducing bacteria produce hydrogen sulfide (H₂S) rather than H₂ or CH₄. This explains why some patients with classic SIBO symptoms — diarrhea, malabsorption, and gas with a characteristic rotten-egg odor — return a completely flat standard breath test. Standard LMBT and GBT equipment doesn't measure H₂S. Diagnosis requires specialized three-gas testing (now available from a small number of labs). Clinically, bismuth compounds and specific antibiotic combinations are used, though the evidence base is thinner than for hydrogen or methane SIBO.

Breath Test Protocols: Lactulose vs. Glucose vs. Methane

Breath testing works because gut bacteria ferment substrates and release gases (H₂, CH₄, H₂S) that are absorbed into the bloodstream and exhaled. By tracking gas concentrations over time after a standard substrate dose, clinicians can infer where fermentation is occurring along the GI tract.

Lactulose Breath Test (LBT)

Lactulose is a synthetic sugar that humans cannot digest — it passes through the entire small intestine before reaching the colon, making it capable of detecting overgrowth anywhere along the transit route. The standard protocol involves consuming 10g lactulose after a 12-hour fast, then providing breath samples every 15-20 minutes for 2-3 hours.

Positive result: Rise of >20ppm H₂ within 90 minutes of ingestion. The Cedars-Sinai protocol extends this to a 3-hour collection window to capture both early peaks (indicating proximal small bowel overgrowth) and late peaks (colonic fermentation, which should be separated from a true early positive by at least a 15-minute flat interval).

Limitation: Rapid intestinal transit can produce a false-positive — the substrate reaches the colon quickly, triggering a hydrogen spike that mimics an early small bowel fermentation signal. This is a well-documented problem, particularly in patients with diarrhea-predominant conditions who already have faster transit.

Glucose Breath Test (GBT)

Glucose is a monosaccharide absorbed entirely in the proximal small intestine under normal conditions. This means the GBT only detects overgrowth in the first 90-100cm of the small bowel — it will miss more distal disease. What it loses in coverage, it gains in specificity.

Positive result: Rise of >12ppm H₂ within 60-90 minutes. Because glucose is absorbed before it reaches the colon, a positive signal is almost certainly from small intestinal bacteria — false-positive rates from rapid transit are substantially lower. The Khoshini meta-analysis (covering multiple prospective studies) placed LBT sensitivity at 52-68% and GBT sensitivity at 62-93%, though specificity estimates vary widely across studies depending on the gold standard used.

Methane Breath Testing

Methane testing uses the same sample collection process as standard H₂ testing — most modern breath test kits measure both gases simultaneously. A reading of ≥10ppm CH₄ at any point during the test (not tied to a specific rise threshold) is the accepted positive criterion for IMO. Because methane is both produced in and absorbed from the colon, the time-to-peak is less informative for localization than in H₂ testing.

Treatment: Antibiotics, Herbals, and Elemental Diet

Rifaximin — The First-Line Antibiotic

Rifaximin (brand name Xifaxan) is the cornerstone of evidence-based SIBO treatment. It's a non-systemic rifamycin antibiotic that remains almost entirely in the GI tract and is not absorbed into the bloodstream, which is why systemic side effects are minimal and resistance development in other body sites isn't a concern.

Standard protocol: 550mg three times daily × 14 days. The TARGET3 trial — the largest randomized controlled trial to date — demonstrated rifaximin's superiority over placebo for IBS-D symptom relief, including bloating and abdominal pain, with a response rate around 40% (versus 23% placebo). These are modest absolute numbers, but they're meaningful in a condition where prior placebo response rates are high and symptom relief is difficult to achieve.

Rifaximin + Neomycin for IMO

Rifaximin alone has limited activity against Methanobrevibacter smithii. Adding neomycin (typically 500mg twice daily for 14 days) targets the archaeon more directly and has been shown to significantly improve methane reduction and constipation outcomes. Some protocols substitute neomycin with metronidazole, though the evidence for the rifaximin + neomycin combination is more robust.

Herbal Antimicrobial Protocols

Several herbal compounds have demonstrated antimicrobial activity against small bowel organisms in vitro and in clinical observational studies. A small but frequently cited head-to-head study found that the combination of FC-Cidal (a thyme/berberine compound) and Dysbiocide produced comparable hydrogen breath test normalization rates to rifaximin in hydrogen-dominant SIBO.

Individual compounds of note include: allicin (from garlic, specifically the allicin-releasing form, not standard garlic powder, typically 450mg three times daily) for methane/IMO due to its archaeicidal properties; berberine (500mg 3× daily) for broad-spectrum antimicrobial and prokinetic effects; and oregano oil (carvacrol-standardized extracts). Herbal protocols typically run 4-6 weeks — longer than the antibiotic course — and are chosen by patients who prefer to avoid antibiotics or have had antibiotic failure.

Elemental Diet

The elemental diet involves consuming a pre-digested liquid formula that provides complete nutrition as amino acids, simple sugars, and fatty acids — nutrients absorbed entirely in the proximal small intestine, leaving nothing for overgrown bacteria to ferment. In a landmark study, 2 weeks of elemental diet produced a normalization rate of approximately 85% on repeat breath testing. This is higher than most antibiotic protocols, though adherence is a significant barrier — the formulas are calorically dense, not palatable to many patients, and expensive when used for 14 days.

Elemental diet is most commonly used when antibiotic courses have failed, when patients cannot tolerate antibiotics, or as a pre-treatment reset before repeating antibiotic therapy.

The Recurrence Problem: MMC, Prokinetics, and Prevention

SIBO's dirty secret is its recurrence rate. Without addressing underlying root causes, studies report recurrence in 40-50% of patients within a year of successful treatment. This is the part of SIBO management that most practitioners underemphasize.

The Migrating Motor Complex

The migrating motor complex (MMC) is a cyclical electrical pattern in the gut that drives peristaltic "cleansing waves" during fasting periods. Its phase III — the most powerful contractile phase — sweeps bacteria, food debris, and cellular material from the small intestine toward the colon roughly every 90-120 minutes during the fasted state. Think of it as the gut's overnight cleaning crew.

When MMC function is impaired — due to diabetes-related autonomic neuropathy, hypothyroidism, scleroderma, post-infectious enteric neuropathy, opioid use, or structural issues like adhesions — bacteria aren't adequately cleared from the small bowel and quickly repopulate. Treating the infection without restoring MMC function virtually guarantees relapse.

Prokinetic Agents Post-Treatment

Low-dose prokinetics taken between meals (when the MMC would normally be active) support phase III activity and are the most evidence-based relapse prevention strategy:

• Low-dose naltrexone (LDN): 1.5–4.5mg nightly — the most widely used off-label prokinetic for SIBO prevention; stimulates opioid growth factor receptors and has anti-inflammatory properties beyond motility.
• Erythromycin: 50-100mg at night (sub-antimicrobial dose) — a motilin receptor agonist that triggers phase III contractions; tachyphylaxis (tolerance) can develop over weeks.
• Ginger (Zingiber officinale): 1000mg of standardized extract — stimulates gastric emptying and has mild motilin-like effects; well-tolerated for long-term use.
• Prucalopride: Prescription 5-HT₄ agonist; evidence-based for slow-transit constipation and useful in IMO where constipation remains post-treatment.

Fasting Windows and Meal Timing

The MMC only activates in the fasted state — eating triggers the fed motility pattern, which is localized and doesn't produce the sweeping phase III waves. This makes meal spacing a genuine therapeutic intervention: allowing at least 4-5 hours between meals with no caloric snacking gives the MMC time to complete full cycles. Time-restricted eating (16:8 or similar patterns) may offer additional benefit by extending the overnight fasting window, though direct SIBO-prevention trials are lacking.